by Taking Control Of Your Diabetes®
Welcome to Taking Control Of Your Diabetes® - The Podcast, an edutaining show all about highs and lows of living with diabetes. Hosted by Dr. Steve Edelman and Dr. Jeremy Pettus, both endocrinologists who have been living with diabetes themselves since they were 15, we’re discussing the important topics that people living with diabetes need to know—and no topic is off-limits. From the latest advancements in diabetes medications and devices, to interviews with some of the best minds in diabetes, to personal stories about the ups and downs of dealing with this condition 24/7, we’re tackling what it means to live with diabetes in modern times. And we promise to make you laugh along the way, because sometimes we just need to laugh at the craziness that comes with living with diabetes. Tune in for a new episode on the last Monday of every month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes! VISIT: tcoyd.org | FOLLOW: tcoyd.org/contact | EMAIL: [email protected] APPLE PODCAST RATING: 4.9/🌟🌟🌟🌟🌟
Language
🇺🇲
Publishing Since
3/25/2022
Email Addresses
1 available
Phone Numbers
0 available
April 30, 2025
<p>In this jam-packed episode, Dr. Jeremy Pettus and Dr. Steve Edelman team up with special guest Dr. David Ahn to break down <strong>the latest and greatest in diabetes technology for 2025</strong>. From extended-wear CGMs to fully automatic hybrid closed-loop pumps and dual-hormonal systems, this episode is your complete guide to what’s available now and what’s coming soon. Whether you’re on MDI, using a pump, or considering a tech upgrade, this conversation will help you <strong>navigate the expanding world of devices—and find the right setup for you</strong>.</p><p><br></p><p><strong>Key Topics:</strong></p><ul><li><strong>Extended-Wear CGMs: </strong>The Dexcom G7 now lasts over 15 days—and the Eversense implantable sensor lasts a full year.</li><li><strong>Over-the-Counter CGMs: </strong>Learn about Dexcom Stelo and Abbott Lingo, designed for people without diabetes.</li><li><strong>New Pump Launches:</strong> Including Tandem Mobi, Beta Bionics iLet, Sequel Twist, and Medtronic’s MiniMed™ 780G with Simplera Sync sensor.</li><li><strong>Medtronic Simplera Sync: </strong>What to know about its U.S. launch, wear time, and integration with the 780G system.</li><li><strong>Dual-Hormone Systems:</strong> Explore how glucagon is being used alongside insulin to prevent lows and simplify diabetes management.</li><li><strong>Ketone Monitoring: </strong>Continuous ketone sensors are on the horizon, and they could change how we detect and prevent DKA.</li><li><strong>Improved App Integration: </strong>Discover updates in CGM and pump interfaces for iPhone and Android, including Libre 3+ and universal app platforms.</li><li><strong>Customizing Your Combo: </strong>Why matching the right CGM with the right pump (or sticking with MDI) is more doable—and more important—than ever.</li></ul><p><br></p><p><strong>Visit TCOYD's Website for more diabetes edutainment for people living with diabetes: </strong><a href="https://tcoyd.org/"><strong>tcoyd.org</strong></a></p><p><strong>**Tune in for two new episodes each month! Like what you hear and want to help us grow? Please rate and review this podcast so we can reach more people living with diabetes!**<br></strong><br><strong>Follow our social media channels to empower yourself with the essential areas of diabetes knowledge led by two endocrinologists living with type 1 diabetes: </strong><a href="https://www.facebook.com/TCOYD/"><strong>Facebook</strong></a><strong> | </strong><a href="https://www.instagram.com/tcoyd/"><strong>Instagram</strong></a><strong> | </strong><a href="https://www.youtube.com/channel/UC4WWhIDg18gP9ZC-IeqmYNQ"><strong>YouTube</strong></a></p> <strong> <a href="https://tcoyd.org/donate-form-pod/" rel="payment" title="★ Support this podcast ★">★ Support this podcast ★</a> </strong>
April 14, 2025
<p>In this episode, Dr. Jeremy Pettus and Dr. Steve Edelman go head-to-head in a friendly face-off between two of the most talked-about medications in diabetes and weight management: Ozempic and Mounjaro. Both are part of the powerful GLP-1 class, but which one might be better for you? From A1C reduction and weight loss to heart and kidney protection, ease of use, side effects, and insurance coverage—Drs. E & P walk you through a category-by-category comparison. They bring the clinical data and their own real-world patient experience to help you understand the key differences (and similarities) between these leading therapies. Whether you're managing type 2 diabetes, living with type 1, or exploring options for weight loss, this episode is designed to help you make an informed decision with your healthcare provider.</p><p><strong>Key Topics:</strong></p><ul><li>How These Medications Work: Learn the difference between GLP-1 and dual agonist therapies</li><li>A1C Reduction: See which drug leads to greater blood sugar improvements based on head-to-head clinical trials.</li><li>Weight Loss: Discover how much weight patients lose on each medication—and why Mounjaro often shows stronger results.</li><li>Heart Health: Understand which medication has FDA approval for cardiovascular protection and what’s still under investigation.</li><li>Kidney Protection: Explore the latest studies showing Ozempic’s ability to slow kidney disease progression.</li><li>Side Effects: Get practical tips on managing common GI side effects and why titration matters.</li><li>Ease of Use: Compare how the pens work, dosing flexibility, and what may be easier for patients day to day.</li><li>Sleep Apnea: Find out how Mounjaro earned a new indication for reducing sleep apnea severity—especially through weight loss.</li><li>Access for Type 1s: Learn why these meds aren’t yet approved for T1D and how some patients are still getting them.</li><li>Emerging Indications: Hear about new uses for these meds, including fatty liver, osteoarthritis, and even alcohol reduction.</li><li>How to Choose: Get expert guidance on which medication may be right for you based on your goals and health needs.</li></ul> <strong> <a href="https://tcoyd.org/donate-form-pod/" rel="payment" title="★ Support this podcast ★">★ Support this podcast ★</a> </strong>
March 24, 2025
<p>In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus sit down with <strong>Sierra Werling, their first patient to ever receive Tzield, to discuss the groundbreaking therapy designed to delay the onset of type 1 diabetes</strong>. Sierra shares her personal journey, how she discovered she was at risk for type 1, what led her to pursue the Tzield treatment, and how her life has changed since receiving it. Steve and Jeremy also break down the science behind Tzield, how it works to <strong>preserve insulin-producing beta cells</strong>, and why <strong>early screening for type 1 diabetes is more important than ever</strong>. They discuss how delaying the disease can impact long-term health, providing individuals more time to prepare, access new treatments, and potentially reduce complications in the future. This episode highlights a major shift in diabetes care, one that moves beyond just managing type 1 diabetes to proactively delaying its onset. Tune in to hear Sierra’s experience, insights, and <strong>what this means for the future of diabetes prevention</strong>.</p><p><br></p><p><strong>Key Topics:</strong></p><ul><li>What is Tzield, and how does it work to delay type 1 diabetes?</li><li>Sierra’s journey: From early screening to Tzield infusion</li><li>Understanding the stages of type 1 diabetes, where does Tzield fit in?</li><li>How delaying type 1 diabetes impacts long-term health and quality of life</li><li>The emotional and practical benefits of early T1D intervention</li><li>Why screening for type 1 diabetes is critical, even without a family history</li><li>Sierra’s personal insights, what she learned from the process, and what she wants others to know</li><li>What’s next for Tzield and other potential disease-modifying therapies?</li></ul><p>Screen today: <a href="https://www.screenfortype1.com/">https://www.screenfortype1.com/</a></p> <strong> <a href="https://tcoyd.org/donate-form-pod/" rel="payment" title="★ Support this podcast ★">★ Support this podcast ★</a> </strong>
Scott Benner
American Diabetes Association
Integrated Diabetes Services
Stacey Simms
Wendy Lopez, Jessica Jones
Docs Who Lift
Reverse insulin resistance permanently
Nutritional Weight & Wellness, Inc.
Physicians Committee
Justin Eastzer
PodcastOne
Dr. Eric Berg
QuickAndDirtyTips.com, Monica Reinagel
Rip Esselstyn
The Washington Post
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.